162 related articles for article (PubMed ID: 31618395)
1. PHYSICAL ACTIVITY IN DAILY LIFE, EXERCISE CAPACITY AND QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE ON INFLIXIMAB-INDUCED REMISSION: A PRELIMINARY STUDY.
Cabalzar AL; Azevedo FM; Lucca FA; Reboredo MM; Malaguti C; Chebli JMF
Arq Gastroenterol; 2019; 56(4):351-356. PubMed ID: 31618395
[TBL] [Abstract][Full Text] [Related]
2. Infliximab-induced remission improves physical activity in patients with active Crohn's disease.
Lucca FA; Malaguti C; Chebli LA; Reboredo MM; Pinheiro BV; Ribeiro TCDR; Azevedo FM; Corrêa JODA; Gaburri PD; Chebli JMF
Rev Assoc Med Bras (1992); 2020 Nov; 66(11):1566-1572. PubMed ID: 33295411
[TBL] [Abstract][Full Text] [Related]
3. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
[TBL] [Abstract][Full Text] [Related]
4. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
Suzuki Y; Matsui T; Ito H; Ashida T; Nakamura S; Motoya S; Matsumoto T; Sato N; Ozaki K; Watanabe M; Hibi T
Inflamm Bowel Dis; 2015 Sep; 21(9):2114-22. PubMed ID: 26218144
[TBL] [Abstract][Full Text] [Related]
5. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
Lichtenstein GR; Yan S; Bala M; Hanauer S
Am J Gastroenterol; 2004 Jan; 99(1):91-6. PubMed ID: 14687148
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
7. [Acute appendicitis in a patient with perianal Crohn's disease receiving infliximab].
Szakács Z; Faluhelyi N; Fincsur A; Papp A; Vincze Á; Bajor J
Orv Hetil; 2018 Mar; 159(10):405-409. PubMed ID: 29504422
[TBL] [Abstract][Full Text] [Related]
8. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
9. [Infliximab in the treatment of patients with Crohn's disease: preliminary report].
Gellona V J; Zarraonandia A A; Zúñiga D A; Palma C R; Contreras P J; Silva Ch J; González D R; Quintana V C
Rev Med Chil; 2006 Mar; 134(3):320-5. PubMed ID: 16676104
[TBL] [Abstract][Full Text] [Related]
10. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
11. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
13. Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease.
van Balkom BP; Schoon EJ; Stockbrügger RW; Wolters FL; van Hogezand RA; van Deventer SJ; Oldenburg B; van Dullemen HM; Russel MG
Aliment Pharmacol Ther; 2002 Jun; 16(6):1101-7. PubMed ID: 12030951
[TBL] [Abstract][Full Text] [Related]
14. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
[TBL] [Abstract][Full Text] [Related]
15. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
16. [Anti-TNF therapy in treatment of luminal Crohn's disease].
Marko B; Prka L
Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
[TBL] [Abstract][Full Text] [Related]
17. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
[TBL] [Abstract][Full Text] [Related]
18. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
19. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
Panaccione R;
Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
